Product nameAnti-Nmnat1/NMNAT antibody [OTI1F7]
See all Nmnat1/NMNAT primary antibodies
DescriptionMouse monoclonal [OTI1F7] to Nmnat1/NMNAT
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Human
Recombinant full length protein corresponding to Human Nmnat1/NMNAT aa 1-279. Produced in HEK-293T cells (NP_073624).
MENSEKTEVVLLACGSFNPITNMHLRLFELAKDYMNGTGRYTVVKGIISP VGDAYKKKGLIPAYHRVIMAELATKNSKWVEVDTWESLQKEWKETLKVLR HHQEKLEASDCDHQQNSPTLERPGRKRKWTETQDSSQKKSLEPKTKAVPK VKLLCGADLLESFAVPNLWKSEDITQIVANYGLICVTRAGNDAQKFIYES DVLWKHRSNIHVVNEWIANDISSTKIRRALRRGQSIRYLVPDLVQEYIEK HNLYSSESEDRNAGVILAPLQRNTAEAKT
Database link: Q9HAN9
- WB: Nmnat1/NMNAT transfected HEK-293T cell lysate. ICC/IF: COS-7 cells transiently transfected with Nmnat1/NMNAT.
Clone OTI1F7 (formerly 1F7).
This product was previously labelled as Nmnat1
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: PBS, 1% BSA, 50% Glycerol
Concentration information loading...
Purification notesPurified from cell culture supernatant by affinity chromatography.
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab118270 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000. Predicted molecular weight: 31 kDa.|
FunctionCatalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747). Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747). Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747). Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) (PubMed:17402747). Protects against axonal degeneration following mechanical or toxic insults.
Tissue specificityWidely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.
PathwayCofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.
Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+) from nicotinate D-ribonucleotide: step 1/1.
Involvement in diseaseLeber congenital amaurosis 9
Sequence similaritiesBelongs to the eukaryotic NMN adenylyltransferase family.
- Information by UniProt
- EC 126.96.36.199 antibody
- LCA9 antibody
- Leber's congenital amaurosis 9 antibody
All lanes : Anti-Nmnat1/NMNAT antibody [OTI1F7] (ab118270) at 1/2000 dilution
Lane 1 : pCMV6-ENTRY control cDNA transfected HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) cell lysate
Lane 2 : pCMV6-ENTRY Nmnat1/NMNAT cDNA transfected HEK-293T cell lysate
Lysates/proteins at 5 µg per lane.
Predicted band size: 31 kDa
pCMV6-ENTRY Nmnat1/NMNAT cDNA transfected COS-7 (African green monkey kidney fibroblast-like cell line) cells stained for Nmnat1/NMNAT using ab118270 at a 1/100 dilution in ICC/IF.
ab118270 has not yet been referenced specifically in any publications.